Evaxion A/S SEC filings EVAX
Evaxion A/S has 364 filings in SEC EDGAR's recent list, going back to Oct 22, 2020. Its latest annual report, Form 20-F, was filed on Mar 5, 2026 for the period ended Dec 31, 2025. The most recent current report (Form 6-K) was filed on Nov 4, 2026. The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| EFFECT | Filing | Mar 24, 2025 | — |
| CORRESP | Letter to the SEC | Mar 20, 2025 | — |
| UPLOAD | Letter from the SEC | Mar 19, 2025 | — |
| EFFECT | Filing | Jan 29, 2025 | — |
| CORRESP | Letter to the SEC | Jan 28, 2025 | — |
| UPLOAD | Letter from the SEC | Nov 22, 2024 | — |
| EFFECT | Filing | Aug 22, 2024 | — |
| CORRESP | Letter to the SEC | Aug 20, 2024 | — |
| CORRESP | Letter to the SEC | Jul 22, 2024 | — |
| UPLOAD | Letter from the SEC | May 17, 2024 | — |
| EFFECT | Filing | Feb 1, 2024 | — |
| CORRESP | Letter to the SEC | Jan 30, 2024 | — |
| UPLOAD | Letter from the SEC | Jan 18, 2024 | — |
| EFFECT | Filing | Aug 30, 2023 | — |
| EFFECT | Filing | Aug 26, 2022 | — |
| CORRESP | Letter to the SEC | Aug 24, 2022 | — |
| UPLOAD | Letter from the SEC | Jul 12, 2022 | — |
| EFFECT | Filing | Jun 3, 2022 | — |
| CORRESP | Letter to the SEC | Jun 1, 2022 | — |
| UPLOAD | Letter from the SEC | May 27, 2022 | — |
| EFFECT | Filing | Nov 4, 2021 | — |
| CORRESP | Letter to the SEC | Nov 3, 2021 | — |
| CORRESP | Letter to the SEC | Nov 3, 2021 | — |
| CORRESP | Letter to the SEC | Oct 29, 2021 | — |
| CORRESP | Letter to the SEC | Oct 29, 2021 | — |
| UPLOAD | Letter from the SEC | Jun 29, 2021 | — |
| DRSLTR | Filing | Jun 25, 2021 | — |
| DRS | Filing | Jun 25, 2021 | — |
| SEC STAFF LETTER | Filing | Feb 5, 2021 | — |
| EFFECT | Filing | Feb 4, 2021 | — |
| CERT | 8a cert | Feb 3, 2021 | — |
| CORRESP | Letter to the SEC | Feb 2, 2021 | — |
| CORRESP | Letter to the SEC | Feb 2, 2021 | — |
| CORRESP | Letter to the SEC | Feb 1, 2021 | — |
| UPLOAD | Letter from the SEC | Jan 28, 2021 | — |
| 8-A12B | Filing | Jan 26, 2021 | — |
| CORRESP | Letter to the SEC | Jan 22, 2021 | — |
| SEC STAFF LETTER | Filing | Jan 6, 2021 | — |
| DRSLTR | Filing | Jan 4, 2021 | — |
| DRS/A | Filing | Jan 4, 2021 | — |
| UPLOAD | Letter from the SEC | Dec 22, 2020 | — |
| DRS/A | Filing | Dec 16, 2020 | — |
| DRSLTR | Filing | Dec 15, 2020 | — |
| UPLOAD | Letter from the SEC | Dec 7, 2020 | — |
| DRSLTR | Filing | Nov 25, 2020 | — |
| DRS/A | Filing | Nov 25, 2020 | — |
| UPLOAD | Letter from the SEC | Nov 18, 2020 | — |
| DRSLTR | Filing | Oct 22, 2020 | — |
| DRS | Filing | Oct 22, 2020 | — |
Showing 49 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Biological Products, (No Diagnostic Substances) (SIC 2836)
- Listed as
- EVAX (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- Denmark
- Headquarters
- Hoersholm
- SEC filer status
- Non-accelerated filer, Emerging growth company
- SEC CIK
- 1828253
- Former names
- Evaxion Biotech A/S (until May 5, 2025)
Other Biological Products, (No Diagnostic Substances) companies
- Amgen Inc AMGN
- Gilead Sciences, Inc. GILD
- Moderna, Inc. MRNA
- Argenx SE ARGX
- Revolution Medicines, Inc. RVMD
- Biogen Inc. BIIB
- BioNTech SE BNTX
- Exelixis, Inc. EXEL
All 182 Biological Products, (No Diagnostic Substances) companies
Source: SEC EDGAR filings. This is company-reported data, not investment advice.